48,830
edits
Difference between revisions of "Intraductal carcinoma of the prostate"
Jump to navigation
Jump to search
Intraductal carcinoma of the prostate (view source)
Revision as of 19:04, 13 April 2018
, 19:04, 13 April 2018→General: +prevalence
(→General: +prevalence) |
|||
| Line 41: | Line 41: | ||
**For comparison: HGPIN ~70% agreement, invasive carcinoma ~73% agreement. | **For comparison: HGPIN ~70% agreement, invasive carcinoma ~73% agreement. | ||
*Uncommon finding ~ 3% of cases in a series of 1176 prostate biopsies.<ref name=pmid23931616>{{Cite journal | last1 = Watts | first1 = K. | last2 = Li | first2 = J. | last3 = Magi-Galluzzi | first3 = C. | last4 = Zhou | first4 = M. | title = Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. | journal = Histopathology | volume = 63 | issue = 4 | pages = 574-9 | month = Oct | year = 2013 | doi = 10.1111/his.12198 | PMID = 23931616 }}</ref> | *Uncommon finding ~ 3% of cases in a series of 1176 prostate biopsies.<ref name=pmid23931616>{{Cite journal | last1 = Watts | first1 = K. | last2 = Li | first2 = J. | last3 = Magi-Galluzzi | first3 = C. | last4 = Zhou | first4 = M. | title = Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. | journal = Histopathology | volume = 63 | issue = 4 | pages = 574-9 | month = Oct | year = 2013 | doi = 10.1111/his.12198 | PMID = 23931616 }}</ref> | ||
===Prevalence=== | |||
Prevalence varies by risk/stage - based on a systematic review by Porter ''et al.'':<ref name=pmid28342640>{{Cite journal | last1 = Porter | first1 = LH. | last2 = Lawrence | first2 = MG. | last3 = Ilic | first3 = D. | last4 = Clouston | first4 = D. | last5 = Bolton | first5 = DM. | last6 = Frydenberg | first6 = M. | last7 = Murphy | first7 = DG. | last8 = Pezaro | first8 = C. | last9 = Risbridger | first9 = GP. | title = Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. | journal = Eur Urol | volume = 72 | issue = 4 | pages = 492-495 | month = Oct | year = 2017 | doi = 10.1016/j.eururo.2017.03.013 | PMID = 28342640 }}</ref> | |||
{| class="wikitable sortable" | |||
! Group | |||
! Prevalence | |||
|- | |||
| WHO1 | |||
| 2% | |||
|- | |||
| WHO2 or WHO3 | |||
| 23% | |||
|- | |||
| WHO4 or WHO5 | |||
| 37% | |||
|- | |||
| metastasis/recurrence | |||
| 56% | |||
|} | |||
==Microscopic== | ==Microscopic== | ||